AVIR (Atea Pharmaceuticals) Current Deferred Taxes Liabilities: $0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AVIR Atea Pharmaceuticals Inc AVIR
24 GF Score
Price $4.61
! 3 Warning Signs
View Full Analysis

What is Atea Pharmaceuticals Current Deferred Taxes Liabilities?

Atea Pharmaceuticals AVIR -1.91% 24 Current Deferred Taxes Liabilities is $0.00 Mil as of Mar. 2026. GuruFocus rates AVIR with a GF Score™ of 24/100. The stock has 3 warning signs investors should review.

Current Deferred Taxes Liabilities represent future tax liabilities, resulting from temporary differences between book (accounting) value of assets and liabilities and their tax value, or timing differences between the recognition of gains and losses in financial statements and their recognition in a tax computation. Deferred tax liabilities generally arise where tax relief is provided in advance of an accounting expense, or income is accrued but not taxed until received.

Atea Pharmaceuticals's current deferred tax liabilities for the quarter that ended in Mar. 2026 was $0.00 Mil.

Atea Pharmaceuticals Current Deferred Taxes Liabilities Related Terms

Atea Pharmaceuticals Current Deferred Taxes Liabilities Historical Data

* Premium members only.

The historical data trend for Atea Pharmaceuticals's Current Deferred Taxes Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atea Pharmaceuticals Current Deferred Taxes Liabilities Chart

Atea Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Taxes Liabilities
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Atea Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Deferred Taxes Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
AVIR
24GF Score
Atea Pharmaceuticals Inc AVIR
Current Deferred Taxes Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Taxes Liabilities of $0.00 Mil mean?
Atea Pharmaceuticals (AVIR) has a Current Deferred Taxes Liabilities of $0.00 Mil as of Mar. 2026. Current Deferred Tax Liabilities records the total amount of taxes due for the period but not yet paid. View historical data on Atea Pharmaceuticals and its competitors.
Is Atea Pharmaceuticals' Current Deferred Taxes Liabilities too high?
Atea Pharmaceuticals' current Current Deferred Taxes Liabilities is $0.00 Mil. Overall, Atea Pharmaceuticals has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Atea Pharmaceuticals' Current Deferred Taxes Liabilities compare to STRO and IPSC?
Atea Pharmaceuticals' Current Deferred Taxes Liabilities of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Taxes Liabilities for a Biotechnology company?
A good Current Deferred Taxes Liabilities depends on the Biotechnology industry context. However, Current Deferred Taxes Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Taxes Liabilities mean?
A high Current Deferred Taxes Liabilities can signal that a stock is expensive relative to its fundamentals. Current Deferred Tax Liabilities records the total amount of taxes due for the period but not yet paid. View historical data on Atea Pharmaceuticals and its competitors. Atea Pharmaceuticals's current Current Deferred Taxes Liabilities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atea Pharmaceuticals stock overvalued right now?
Atea Pharmaceuticals (AVIR) has a current Current Deferred Taxes Liabilities of $0.00 Mil. The current Current Deferred Taxes Liabilities is $0.00 Mil. Atea Pharmaceuticals' overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Taxes Liabilities calculated?
Current Deferred Taxes Liabilities is calculated from a company's financial statements. For Atea Pharmaceuticals (AVIR), the current Current Deferred Taxes Liabilities is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Atea Pharmaceuticals Business Description

Address 225 Franklin Street, Suite 2100, Boston, MA, USA, 02110
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
24GF Score

Get the complete analysis for AVIR

Current Deferred Taxes Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.61
Price